Chewy vs. Coupang: Which Consumer Stock Is a Better Buy in 2026?

Chewy is presented as the preferred 2026 investment, with consensus forecasting fiscal 2026 sales growth of 7% to $13.5 billion and nearly 50% net-income growth to $333 million. Its FY2025 revenue rose about 6% to $12.6 billion, while the Modern Animal acquisition expands its veterinary-clinic footprint toward 47 locations and supports a broader pet-health strategy. Chewy trades at a 16.3x forward P/E versus Coupang's 75.8x, although both trade at 0.8x sales; Coupang faces near-term pressure from a distribution-center fire, a 33 million-account data incident, and expectations for a fiscal 2026 net loss.

Analysis

CHWY’s apparent valuation advantage is only durable if veterinary expansion raises gross profit per active customer rather than merely adding a low-scale, labor-intensive clinic footprint. The key underwriting variable is clinic-level contribution after veterinarian compensation, occupancy, and acquisition integration—not revenue growth. A successful care/pharmacy loop could lift retention and private-label penetration over 6-18 months, but the near-term earnings setup is vulnerable because a modest miss in clinic ramp costs or pet discretionary demand would matter disproportionately to a low-net-margin business.

CPNG is the more asymmetric operational recovery, but not yet the cleaner long. The relevant signal is cohort reactivation and WOW-member order frequency following the service and trust disruptions, not headline membership alone; memberships can be defended through promotions that delay margin recovery. If core Korean commerce normalizes while Taiwan losses narrow, operating leverage could make current sales-based valuation look inexpensive over 12-24 months. Conversely, a regulatory remedy that structurally limits marketplace self-preferencing, combined with customer-compensation costs, would impair the network economics that justify its premium earnings multiple.

Consensus likely underweights CHWY’s balance-sheet and cash-conversion quality relative to its headline forward P/E: a sub-1 current ratio and substantial SBC add-back reduce the margin for execution error during an acquisition-led expansion. It also underweights CPNG’s embedded cloud concentration—an AWS pricing or outage event is operationally amplified by its promise of rapid fulfillment. The cleaner relative expression is therefore CHWY versus CPNG only after verifying that CHWY clinic economics are accretive and CPNG’s repeat-purchase metrics, not just user counts, are stabilizing.

Key Decisions for Investors

• Maintain a modest long CHWY only into the next two earnings reports; add on evidence that veterinary/health gross margin and Autoship customer economics improve without a material increase in fulfillment or SG&A intensity. Target 15-20% upside from multiple stability plus earnings delivery; exit if FY2026 operating-margin guidance falls or clinic ramp losses force a meaningful EBITDA revision.
• Keep CPNG on a recovery watch rather than initiate a core long. Trigger a 6-12 month position only if Korean active-customer/order-frequency disclosures stabilize and management quantifies data-incident compensation within existing reserves; upside is material if operating leverage returns, but a further regulatory fine, worsening retention, or Taiwan-loss expansion invalidates the thesis.
• For relative-value exposure, consider long CHWY / short CPNG in equal dollar size over the next 1-3 months if CHWY confirms acquisition integration milestones while CPNG reports weak customer reactivation. This isolates execution-quality divergence; cover the short if CPNG shows sequential core-commerce margin expansion alongside stable retention.
• Avoid treating either company’s reported free cash flow as fully distributable until SBC dilution and working-capital normalization are reconciled. Monitor share-count growth, clinic capex, CPNG fulfillment capex, and AWS-related operating-cost trends before increasing gross exposure.